| Revista: | Memorias do Instituto Oswaldo Cruz |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000437145 |
| ISSN: | 0074-0276 |
| Autors: | Senger, Mario Roberto1 Evangelista, Tereza Cristina Santos2 Dantas, Rafael Ferreira1 Santana, Marcos Vinicius da Silva1 Gonçalves, Luiz Carlos Saramago1 Souza-Neto, Lauro Ribeiro de1 Ferreira, Sabrina Baptista2 Silva-Junior, Floriano Paes1 |
| Institucions: | 1Fundacao Oswaldo Cruz, Instituto Oswaldo Cruz, Rio de Janeiro. Brasil 2Universidade Federal do Rio de Janeiro, Instituto de Quimica, Rio de Janeiro. Brasil |
| Any: | 2020 |
| Volum: | 115 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, prospectivo |
| Resumen en inglés | Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious infection that may break the healthcare system of several countries. Here, we aimed at presenting a critical view of ongoing drug repurposing efforts for COVID-19 as well as discussing opportunities for development of new treatments based on current knowledge of the mechanism of infection and potential targets within. Finally, we also discuss patent protection issues, cost effectiveness and scalability of synthetic routes for some of the most studied repurposing candidates since these are key aspects to meet global demand for COVID-19 treatment |
| Disciplines | Medicina |
| Paraules clau: | Farmacología, Neumología, COVID-19, SARS-CoV-2, Dianas moleculares, Desarrollo de fármacos, Ciclo de replicación |
| Keyword: | Pharmacology, Pneumology, COVID-19, SARS-CoV-2, Drug development, Replication cycle, Molecular targets |
| Text complet: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
